



Published in final edited form as:

J Biomed Nanotechnol. 2018 May 01; 14(5): 900–909. doi:10.1166/jbn.2018.2498.

Intrinsically Zirconium-89-Labeled Manganese Oxide Nanoparticles for *In Vivo* Dual-Modality Positron Emission Tomography and Magnetic Resonance Imaging

Yonghua Zhan^{#1}, Emily B. Ehlerding^{#2}, Sixiang Shi³, Stephen A. Graves², Shreya Goel³, Jonathan W. Engle², Jimin Liang^{1,*}, and Weibo Cai^{2,3,*}

¹Engineering Research Center of Molecular and Neuro Imaging of the Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710071, China

²Department of Medical Physics, University of Wisconsin-Madison, WI, 53705, USA

³Department of Radiology, University of Wisconsin-Madison, WI, 53705, USA

These authors contributed equally to this work.

Abstract

Manganese-based nanoparticles (NPs) have recently attracted much attention in the field of biomedical imaging due to their impressive enhanced T_1 contrast ability. Although the reported manganese-based NPs have exhibited good imaging capabilities as contrast agents, it is still urgent to develop novel multifunctional manganese-based imaging probes for future biomedical imaging, especially PET/MRI probes. Herein, we present chelator-free zirconium-89 (^{89}Zr , $t_{1/2}$: 78.4 h) labeling of manganese oxide NPs (Mn_3O_4 @PEG) with ~78% labeling yield and good stability. Serial positron emission tomography (PET) and magnetic resonance imaging (MRI) studies non-invasively assessed the biodistribution patterns of the NPs and the feasibility of *in vivo* dual-modality imaging and lymph-node mapping. Since Mn_3O_4 NPs exhibited desirable properties for enhanced T_1 imaging and the simplicity of chelator-free radiolabeling, [^{89}Zr] Mn_3O_4 @PEG NPs offer a novel, simple, safe and accurate nanoplatforms for future precise cancer imaging and diagnosis.

Keywords

Manganese Oxide Nanoparticles; Positron Emission Tomography; Magnetic Resonance Imaging; Zirconium-89; Chelator-Free

* Authors to whom correspondence should be addressed. jimleung@mail.xidian.edu.cn, wcai@uwhealth.org.

Conflict of Interest

The authors confirm that there are no known conflicts of interest associated with this publication. Funding sources had no involvement in study design; collection, analysis, and interpretation of data; writing of the report; and in the decision to submit the article for publication.

INTRODUCTION

In the past decades, molecular imaging techniques have demonstrated great value in the early detection and diagnosis of disease, which is attributed to their fast and accurate diagnostic abilities at the molecular and cellular levels.^{1–3} Among them, the integration of PET and MRI has been under rapid development and is currently in clinical trials for applications in cancer detection and diagnosis due to the very high sensitivity of PET and the ultra-high spatial resolution of MRI.^{4,5} To take advantage of the hybrid PET/MRI imaging technology, design and synthesis of novel multifunctional PET/MRI nanoprobe has been a hot research topic since their emergence in the last decade.^{6–8} As one half of the PET/MRI nanoprobe, current MRI contrast agents are commonly in the forms of T_1 -positive contrast agents and T_2 -negative contrast agents.⁹ In particular, T_2 contrast agents based on superparamagnetic iron oxide NPs (SPIONs) have been widely used as the MRI contrast component in PET/MRI probes over the last two decades and a few have advanced into clinical trials or received the approval of the Food and Drug Administration (FDA) of the United States.^{10–12} However, these magnetic-based PET/MRI nanoprobe have been somewhat limited in clinical applications due to their drawbacks of signal-decreasing effects and high susceptibility. Therefore, it is desirable to develop novel PET/MRI nanoprobe with higher T_1 or T_2 relaxivity to meet the future clinical requirements.

Recently, manganese-based NPs have emerged as a new class of T_1 -weighted contrast agents thanks to their relatively high magnetization spins and fast water proton exchange rates.¹³ Meanwhile, manganese-based agents also exhibit good biocompatibility and low side effects because manganese itself is an essential component of cells and a cofactor for many metabolic enzymes, which is attributed to the dissolution of the manganese oxide nanocrystal at low pH.^{13,14} Most importantly, manganese-based NPs with good crystallinity and uniformity have been demonstrated to be easily synthesized on a large scale under mild and ambient reaction conditions.¹⁵ This new promising class of MRI contrast agents, particularly manganese oxides, opens a new direction in biomedical imaging and tumor-targeted diagnosis for future medicine.^{14,16} Progress in developing multimodality imaging probes and their applications in biomedical imaging have been reported in recent years. For example, solid and hollow MnO-based T_1 NP contrast agents have been reported for selectively imaging breast cancer cells and for drug delivery by several groups.^{17–22} Yang and co-workers further developed silica-coated Mn₃O₄ core-shell NPs for tumor folate-receptor-targeted MRI and fluorescent imaging *in vitro* and tumor aptamer-receptor-targeted MRI imaging *in vivo*.^{23–25} Despite many desirable properties for biomedical applications, there are currently few reports related to the fusion of PET tracers (radionuclides) and manganese oxide-based T_1 contrast agents into one single probe for *in vivo* biomedical imaging. Therefore, it is of vital importance to develop novel dual-modality PET/MRI imaging probes based on manganese oxide NPs.

Chelator-based methods have been largely employed for radiolabeling NPs in the past. For example, by using NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid), DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), or desferrioxamine B (DFO) as the chelator, Cu-64 and Zr-89 have been used to label graphene oxide,²⁶ SPIONs,¹² mesoporous silica NPs,²⁷ and monoclonal antibodies (mAb),²⁸ for preclinical studies. However,

potential dissociation of these radionuclides from NPs could easily lead to false interpretation of PET imaging results *in vivo*. For example, significant bladder and bone uptake have been observed during *in vivo* PET imaging of ^{64}Cu -DOTA-Au@PEG NPs²⁹ and ^{89}Zr -DFO-mAb^{30–32} respectively, indicating that the radionuclides dissociated from their respective chelator. To address this concern, recent successful syntheses of intrinsically radiolabeled NPs (i.e., without the use of a chelator) have been reported, such as ^{64}Cu -labeled porphyrins³³ and CuS NPs,³⁴ ^{72}As and ^{69}Ge -labeled SPIONs,^{35,36} and ^{89}Zr -labeled mesoporous silica NPs,³⁷ $\text{Gd}_2\text{O}_3\text{:Eu}$ NPs, and WS_2/WO_x nanodots.^{38–40} These NPs have exhibited great potential in providing a facile, faster, more stable, and more specific radiolabeling technique for future clinical applications. Inspired by these successes, we were encouraged to develop radio-labeled NPs with manganese oxide-based T_1 contrast components for *in vivo* biomedical applications.

In this work, we hypothesized that mixing suitable water-soluble manganese oxide NPs with ^{89}Zr would yield ^{89}Zr -labeled manganese oxide ($[\text{}^{89}\text{Zr}]\text{Mn}_3\text{O}_4\text{@PEG}$) NPs because of the specific affinity of ^{89}Zr for the manganese oxide surface (Scheme 1).^{37–40} Subsequently, systematic *in vivo* PET/MRI imaging, biodistribution, and lymph node mapping studies were carried out in normal healthy BALB/c mice to evaluate their potential capabilities as novel dual-modality PET/MRI agents, and further validated through various *in vitro* and *ex vivo* experiments. Moreover, serum biochemistry assays and histological assessments were also carried out to determine the potential toxicity of these NPs.

EXPERIMENTAL SECTION

Materials

Oleylamine (technical grade 90%), oleic acid (technical grade 90%), xylene (98%), manganese (II) acetate (98%), and the CCK-8 assay were all purchased from Sigma-Aldrich. DSPE-PEG₅₀₀₀-NH₂ was purchased from Creative PEGworks (Winston Salem, NC). PD-10 desalting columns was acquired from GE Healthcare. All buffers and water were of Millipore grade. All chemicals were used as received without further purification.

Characterization

The size and morphology of Mn_3O_4 NPs were observed using an FEIT12 transmission electron microscope (TEM) operated at an accelerating voltage of 120 kV. X-ray diffraction (XRD) measurements were performed on a Bruker D8 diffractometer with $\text{Cu K}\alpha$ radiation ($\lambda = 0.15405$ nm). The surface zeta potential and hydrodynamic size were measured using a Malvern Zetasizer Nano ZS. The T_1 -relaxivities were measured and T_1 -weighted images were acquired with a conventional spin echo acquisition (repetition time, TR, 1000 ms) with echo time, TE, of 50 ms, and a section thickness of 1 mm in a 7 T Bruker Micro-MR small animal scanner. Relaxivity values of r_1 were calculated through curve fitting of $1/T_1$ relaxation time (s^{-1}) versus the Mn concentration (mM).

Synthesis of the $\text{Mn}_3\text{O}_4\text{@PEG}$ NPs

Mn_3O_4 NPs were prepared according to a previously reported method with slight modifications.¹⁴ In brief, manganese (II) acetate (1 mmol, 0.17 g) and a mixture of oleic

acid (2 mmol, 0.57 g) and oleylamine (10 mmol, 2.67 g) were dissolved in 15 mL of xylene in air atmosphere. After slowly heating to 95 °C, 1 mL of DI water was injected into the solution under brisk stirring, and the resulting solution was aged at 95 °C for 3 h. A total of 100 mL of ethanol was then added to precipitate the nanocrystals, followed by centrifugation to retrieve the nanocrystals in powder form. 10 mg of Mn₃O₄ nanocrystals were dispersed in 1 mL of chloroform and then added to 20 mg of DSPE-PEG₅₀₀₀-NH₂ in 2 mL chloroform. After stirring for 2–3 h at 25 °C and evaporating the solvent by argon blowing, the residue was kept at 60 °C in vacuum for 30 min. Upon the addition of 15 mL of DI water, a transparent brown solution was generated after sonication for 15 min. After filtration by centrifugation 3 or 4 times, excess DSPE-PEG₅₀₀₀-NH₂ was removed and Mn₃O₄@PEG NPs were obtained.

⁸⁹Zr Labeling and Serum Stability Studies

⁸⁹Zr-oxalate was produced by the University of Wisconsin-Madison cyclotron group. Briefly, a natural yttrium-89 (⁸⁹Y) foil (250 μm, 99.9%) was irradiated with a proton beam to create ⁸⁹Zr via the ⁸⁹Y (*p, n*) ⁸⁹Zr reaction by using a 16 MeV GE PETtrace cyclotron. After isotope separation and purification, ⁸⁹Zr-oxalate was obtained with a specific activity of >20 GBq/μmol. 200 μL of Mn₃O₄@PEG NPs (1 mg/mL) in HEPES buffer (0.1 M, pH 7.5) was mixed with ⁸⁹Zr-oxalate at 75 °C. The final pH value of the mixture was adjusted to 7–8 by using 2 M Na₂CO₃. ⁸⁹Zr labeling yield was monitored and quantified at different time points (from 3 min to 3 h) by using thin layer chromatography (TLC) and a final labeling time of 1 h was selected. The [⁸⁹Zr]Mn₃O₄@PEG NPs could be easily collected by centrifugation at 15,000 rpm for 5 min. To ensure that [⁸⁹Zr]Mn₃O₄@PEG NPs were sufficiently stable for *in vivo* applications, serum stability studies were carried out. [⁸⁹Zr]Mn₃O₄@PEG NPs were incubated in complete mouse serum at 37 °C for up to 48 h, and analysis was performed as previously described.³⁸ The percentage of retained ⁸⁹Zr on the [⁸⁹Zr]Mn₃O₄@PEG NPs was calculated according to the equation [(total radioactivity-radioactivity in filtrate)/total radioactivity] × 100%.

Cell Cytotoxicity Studies of Mn₃O₄@PEG NPs

The cytotoxicity of Mn₃O₄@PEG NPs was assessed with a CCK-8 assay using SGC-7901 cells and HEK-293 cells. Briefly, cells were seeded in 96-well plates at 20,000 cells per well in 200 μL culture medium. The cells were maintained in RPMI-1640 containing 10% fetal bovine serum (FBS) and incubated at 37 °C in a humidified cell culture incubator with 5% CO₂ atmosphere for 24 h. Mn₃O₄@PEG NP solutions with different concentrations from 200 to 1000 μg/mL were added to each well, and the cells were subjected to a CCK-8 assay after being incubated for another 24 h. The cell viability was determined through measuring the absorption at 450 nm using a microplate reader. Cell viability was calculated using: cell viability (%) = (mean absorption value of treatment group/mean absorption value of control) × 100.

***In Vivo* Toxicity Studies of Mn₃O₄@PEG NPs**

The toxicity of Mn₃O₄@PEG NPs to healthy male BALB/c mice was evaluated through injecting Mn₃O₄@PEG NPs (dose: 20 mg/kg) via the tail vein. Mice injected with only PBS served as a control group (*n* = 3). Three mice were sacrificed to collect blood for serum

biochemistry assays on both day 7 and day 14 post-injection. At the same time, major organs from each mouse were harvested and fixed in 4% paraformaldehyde solution for 1 day. These tissues were then embedded in paraffin and stained with hematoxylin and eosin (H&E) and examined using a digital microscope (Leica DM5000). Examined tissues included the heart, liver, spleen, lung, and kidney. The serum chemistry data, including hepatic and kidney function markers, was measured by the University of Wisconsin-Madison Veterinary Hospital.

***In Vivo* PET/MRI Imaging and Biodistribution Studies**

PET scans of BALB/c mice (n = 3 per group) at 0.5, 2, 12, and 48 h post-injection (p.i.) of [⁸⁹Zr]Mn₃O₄@PEG NPs (~100 μCi or 2.7 MBq) were performed using an Inveon rodent model microPET/microCT scanner (Siemens Medical Solutions USA, Inc.) following tail vein injection. Detailed procedures for data acquisition and analysis of the PET data have been reported previously.³⁸ Quantitative data are presented as percentage injected dose per gram of tissue (%ID/g). For *in vivo* lymph node mapping with PET, 40 μL of [⁸⁹Zr]Mn₃O₄@PEG NPs (~60 μCi or 0.81 MBq) was subcutaneously injected into the left footpad of healthy BALB/c mice. Time points of 0.5 h, 2 h and 6 h were selected for serial PET scans. *In vivo* T₁-weighted MR imaging was performed at 0.5 h, 2 h and 6 h post-injection after intravenous injection of 200 μL Mn₃O₄@PEG with a Mn concentration of 1 mM and used a 7 T small animal scanner (Agilent Technologies, Santa Clara, CA) with the following parameters: TR = 500 ms; TE = 12 ms; flip angle = 120°; FOV = 40 mm × 40 mm; matrix = 256 × 256; NEX = 8; slice thickness = 1 mm for axial liver images and 0.5 mm for coronal and cross lymph node mapping. All the animal studies were conducted under a protocol approved by the University of Wisconsin Institutional Animal Care and Use Committee.

RESULTS AND DISCUSSION

Synthesis and Characterization

As shown in Scheme 1, [⁸⁹Zr]Mn₃O₄@PEG NPs were prepared using similar methods to those we have previously reported.^{37,38} The uniform Mn₃O₄ NPs were monodispersed in nonpolar organic solvent (Fig. 1(a), inset) and had a small spherical shape of approximately 8 nm, which was consistent with previous reports.^{14,24,25} Furthermore, the hydrophobic Mn₃O₄ NPs were successfully transferred to the aqueous phase through coating with amine-functionalized PEG lipids (DSPE-PEG₅₀₀₀-NH₂) and showed good stability in aqueous solution (Fig. 1(b), inset). In addition, DLS measurements showed that Mn₃O₄@PEG had a hydrodynamic diameter of 10 ± 3.5 nm, similar to the observation from TEM. Meanwhile, the zeta-potential value of Mn₃O₄@PEG (23.7 ± 3.5 mV) further verified the existence of the NH₂ group. Meanwhile, the stability of Mn₃O₄@PEG NPs was also investigated in PBS and 10% FBS at different temperatures. The results indicated that the particle size of the Mn₃O₄@PEG NPs did not change significantly after two weeks in different media. Figure 1(c) shows the XRD pattern of the Mn₃O₄ NPs. Clearly, all the diffraction peaks of the as-prepared Mn₃O₄ NPs can be indexed as a tetragonal Mn₃O₄ phase (Joint Committee for Powder Diffraction Standards (JCPDS) card no: 24-0734) without metallic manganese or

other oxide phase, which indicates that the as-synthesized Mn_3O_4 NPs are crystalline and of high purity.

Further investigation of the FT-IR spectra of these NPs confirmed the presence of PEG on the surface of Mn_3O_4 NPs (Fig. 1(d)). The sample exhibited a strong band around $\nu = 1105 \text{ cm}^{-1}$, corresponding to the C-O-C asymmetric (ν_{as}) stretching vibration. To examine the effectiveness of the Mn_3O_4 NPs as positive MRI contrast agents, the relaxation properties of Mn_3O_4 NPs in aqueous media were measured by a 7 T MRI scanner. It was clear that Mn_3O_4 @PEG NPs displayed signal enhancement in the T_1 -weighted MR images with increasing Mn concentration (Fig. 2(a)). The r_1 value of the Mn_3O_4 @PEG NPs was calculated from the linear fitting of the measured $1/T_1$ data versus Mn^{2+} concentration as $0.58 \text{ mM}^{-1}\text{s}^{-1}$ (Fig. 2(b)). These values are also similar to those of previously reported Mn_3O_4 NPs, verifying their potential use as a positive MRI contrast agent.^{20,23–25}

Chelator-Free ^{89}Zr -Labeling and Serum Stability Studies

Inspired by our previous reports on the intrinsic radiolabeling of ^{89}Zr to mesoporous silica NPs and $\text{Gd}_2\text{O}_2\text{S}:\text{Eu}$ @PEG NPs^{37,38} and * As and ^{69}Ge to iron oxide NPs^{35,36} we reasonably postulated that [^{89}Zr] Mn_3O_4 @PEG could be easily formed because of the strong and specific affinity of ^{89}Zr for the Mn_3O_4 surface, which was possible attributed to the formation of Zr complexes occupy vacant Mn_3O_4 tetrahedral sites on the octahedrally terminated surface of the magnetite NPs (Scheme 1(b)).³⁷ After mixing water-soluble Mn_3O_4 @PEG with $^{89}\text{Zr}^{4+}$ in HEPES buffer at pH 7–8, the radiolabeling yield of [^{89}Zr] Mn_3O_4 @PEG was then determined at different time intervals through radio-thin layer chromatography (radio-TLC), wherein [^{89}Zr] Mn_3O_4 @PEG ($R_f = 0$) could easily be distinguished from free ^{89}Zr ($R_f = 0.93$) (Fig. 3(b)). The radiolabeling yield of [^{89}Zr] Mn_3O_4 @PEG was found to be over 78% within the first 30 min, and kept slightly increasing after 180 min of incubation (Fig. 3(a), black line). As expected, ^{89}Zr -labeling was also concentration and temperature dependent, with higher concentration and higher incubation temperatures giving higher labeling yield (Figs. 3(a and c)).

To further investigate the stability of ^{89}Zr labeling *in vitro* and the feasibility for *in vivo* applications, a serum stability study of the [^{89}Zr] Mn_3O_4 @PEG NPs was subsequently conducted. After incubation in complete mouse serum at 37°C for 48 h, nearly 67% of ^{89}Zr remained on the Mn_3O_4 @PEG NPs, suggesting good stability of the radiolabeling on the Mn_3O_4 @PEG NPs. Good radiostability in serum indicated that [^{89}Zr] Mn_3O_4 @PEG NPs would have desirable properties *in vivo*.

In Vitro Biocompatibility Studies of Mn_3O_4 @PEG NPs

The cytotoxicity of Mn_3O_4 @PEG NPs was evaluated by a CCK-8 assay with normal cells (HEK-293) and tumor cells (SGC-7901). The concentration-dependent effect of Mn_3O_4 conjugated NPs on the cell viability for 24 h and 48 h was determined. No obvious cytotoxicity of Mn_3O_4 @PEG NPs to HEK-293 and SGC-7901 cells was observed at any studied concentration (from 0.2 to 1 mg mL^{-1} , Fig. 4). Even at the concentration of 1 mg mL^{-1} , the viability for both HEK-293 and SGC-7901 cells still remained above 80%,

indicating that the $\text{Mn}_3\text{O}_4@\text{PEG}$ NPs should have little cytotoxicity at the given concentration range.

***In Vivo* PET/MRI Imaging and Biodistribution Studies**

As we all know, driven by the impending clinical requirement, the perfect combination of PET and MRI has been current under rapid development in clinical cancer detection and diagnosis due to its very high sensitivity of PET and ultra-high spatial resolution of MRI.^{4,5} To validate the feasibility of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ NPs for dual-modality PET/MRI imaging and to investigate their biodistribution pattern *in vivo*, $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ NPs (200 μL , 2.7 MBq) were intravenously injected into healthy BALB/c mice. According to our previously reported method³⁷ time points of 0.5, 2, 24 and 48 h p.i. were chosen for serial PET scans, as seen in Figure 5(a). Since the hydrodynamic diameters of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ NPs are above the cutoff for renal filtration,⁴¹ the route of clearance was mainly through the hepatobiliary pathway for these nanoparticles. Because of this, strong uptake of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ NPs in the liver was observed, at 36.8 ± 2.3 , 32.3 ± 1.8 , 28.7 ± 0.8 and 25.6 ± 0.3 %ID/g at 0.5, 2, 24, and 48 h p.i. respectively, while the spleen radioactivity was also 23.4 ± 0.3 , 28.9 ± 0.5 , 32.5 ± 0.2 , and 37.1 ± 0.3 %ID/g at 0.5, 2, 24, and 48 h p.i. respectively ($n = 3$). While PET imaging provides high sensitivity and quantitative tracking of radiotracers, essential anatomical information is also indispensable for accurate determination of the biodistribution patterns of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$. Biodistribution studies of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ NPs were also conducted at 48 h p.i. to validate the PET results. Dominant uptake of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ NPs by both the liver and spleen was observed, which confirmed that the serial *in vivo* PET imaging accurately reflected the distribution pattern of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ NPs in mice. To further supplement the PET results, MRI with high spatial resolution was used to investigate the $\text{Mn}_3\text{O}_4@\text{PEG}$ NPs in BALB/c mice. As the $\text{Mn}_3\text{O}_4@\text{PEG}$ NPs exhibited significant T_1 signal enhancement *in vitro*. *In vivo* T_1 MR imaging of BALB/c mice was conducted before and after intravenous injection of the $\text{Mn}_3\text{O}_4@\text{PEG}$ NPs at a dose of 20 mg/kg NPs. Since the r_1 value of the $\text{Mn}_3\text{O}_4@\text{PEG}$ NPs was calculated as $0.58 \text{ mM}^{-1}\text{s}^{-1}$, the injection dose was adequate for *in vivo* MR imaging. In view of this, a positive T_1 signal enhancement in the liver was observed at 0.5 h and 2 h post-injection of $\text{Mn}_3\text{O}_4@\text{PEG}$ NPs. However, the signal enhancement in the liver was decreased at 24 h, which could be attributed to the biodegradation and clearance of the NPs (Fig. 5(b)). Moreover, no detectable signal change for the kidney, compared with the same mice prior to the injection of the NPs. In order to further quantify the consistency between the PET and MRI, by extracting the region of interest (ROI) of MRI and compared with the PET, the ROI of PET and MRI was all gradually decreasing at 0.5 h, 2 h and 24 h. This positive correlation between PET and MRI further proved the feasibility of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ NPs for dual-modality PET/MR imaging.

***In Vivo* PET/MRI Imaging of Lymph Node Mapping**

The lymphatic system plays a vital role in resisting disease invasion, and is also a common site for tumor metastasis. Therefore, precise identification of sentinel lymph nodes is of vital importance in both the prediction of cancer metastasis as well as determination of treatment options. Considering the $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ NPs as good dual-modality PET/MRI agent in biodistribution pattern *in vivo*, as a proof-of-concept, $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ NPs were then

used as non-invasive dual-modality PET/MRI probes for lymph node mapping. After [⁸⁹Zr]Mn₃O₄@PEG NPs were subcutaneously injected into the left foot of normal healthy BALB/c mice (50 μL, 1.0 mM of Mn, ~60 μCi), serial PET scans were carried out. As seen from Figure 6(a), accumulation of [⁸⁹Zr]Mn₃O₄@PEG NPs in the popliteal lymph node could clearly be seen at 0.5 h, 2 h and 6 h post-injection (red arrows), with the uptake of [⁸⁹Zr]Mn₃O₄@PEG NPs evaluated to be 7.7 ± 1.3, 15.3 ± 3.6, and 10.5 ± 2.4 %ID g⁻¹, respectively (n = 3) (Fig. 6(b)). On the contrary, the accumulation of [⁸⁹Zr]Mn₃O₄@PEG NPs in paws showed gradual and prominent decreasing after injection of NPs. Meanwhile, the main organ uptake of [⁸⁹Zr]Mn₃O₄@PEG NPs *in vivo* at different time points were also carried out. As seen in Figure 6(b), there was no obvious accumulation such as heart, liver, spleen, lung, kidney, and so on, which was compared with the lymph nodes. The above results further revealed that the accumulation of [⁸⁹Zr]Mn₃O₄@PEG NPs in lymph nodes after injection was primarily due to the small size, which is well suited to uptake by the lymphatics.

Meanwhile, the accumulation of Mn₃O₄@PEG NPs in the sentinel lymph node could also be visualized by MRI, which showed gradual and prominent brightening of the lymph node after injection of Mn₃O₄@PEG NPs (50 μL, 1.0 mM of Mn; Fig. 6(c), red circle). As an internal contrast, the contralateral lymph node (Fig. 6(c), green circle) exhibited no obvious T₁ contrast enhancement at all the same time points observed. In order to further testify the consistency between the PET and MRI, by extracting the region of interest (ROI) of MRI and PET, the ROI of PET and MRI was all gradually increasing at 0.5 h and 2 h, whereas the signal was then decreased at 6 h respectively. This positive correlation between PET and MRI further proved the feasibility of [⁸⁹Zr]Mn₃O₄@PEG NPs for dual-modality PET/MRI of lymph node mapping. Meanwhile, the *ex vivo* biodistribution of [⁸⁹Zr]Mn₃O₄@PEG NPs was also further investigated at 6 h post-injection, and verified a dominant uptake of NPs in the lymph node. Moreover, once the lymph node was located by the PET/MRI images, the area of the lymph node was further dissected for histological analysis. No apparent histological changes, such as lymphocytes, macrophages, neutrophils, and eosinophils, were observed by hematoxylin and eosin (H&E) staining. While the PET/MRI imaging presented herein could only be acquired separately due to the lack of an integrated microPET/microMRI scanner, [⁸⁹Zr]Mn₃O₄@PEG NPs offer huge potential for future cancer patient diagnosis. Meanwhile, through further conjugation with other specific targeting ligands, [⁸⁹Zr]Mn₃O₄@PEG NPs could be additionally improved to enable accurate early diagnosis and targeted radiotherapy of cancers simultaneously.

***In Vivo* Biocompatibility Studies of Mn₃O₄@PEG NPs**

To investigate the potential *in vivo* toxicity of Mn₃O₄@PEG NPs, histological assessment was carried out by injecting Mn₃O₄@PEG NPs (20 mg/kg) in healthy BALB/c mice via the tail vein. PBS injections served as the control. Two weeks after injection, mice were sacrificed and major organs (heart, liver, spleen, lung, and kidneys) of mice were sliced and stained by H&E for histology analysis. As shown in Figure 7, no noticeable tissue or cellular damage was observed in all major organs of mice, as compared to those obtained from the control group. There was no hydropic degeneration of cardiac muscle tissue in the heart samples. Normal liver macrophages also showed no evidence of inflammatory infiltrates.

Meanwhile, there was no pathological changes and pulmonary fibrosis in the spleen and lung samples. Moreover, the glomerulus structure could be distinguished easily in the kidney samples. For further quantitative evaluation, serum biochemistry assays were then also conducted to investigate the influence of Mn_3O_4 @PEG NPs, especially on potential hepatic injury and kidney functions (Fig. 8). Analysis of four primary hepatic function indicators including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bilirubin (TBIL), as well as two kidney function indicators including serum creatinine (CREA) and serum urea (UREA), demonstrated no obvious hepatic or kidney disorders in both the mice treated with Mn_3O_4 @PEG NPs and the control injected with PBS on both day 7 and day 14 post-injection. Although there was somewhat decreased in the level of ALT ($p < 0.05$) and AST on day 7 and day 14, as compared to those obtained from the control group, it was still within the normal range. These above results also suggested that Mn_3O_4 @PEG NPs demonstrated no obvious toxicity in mice and may be a safe agent for biomedical imaging.

CONCLUSION

In conclusion, using Mn_3O_4 as a nanopatform, we have developed a novel, efficient, chelator-free radiolabeling method to prepare the biocompatible T_1 -MRI and PET contrast agent, $^{89}\text{Zr}[\text{Mn}_3\text{O}_4\text{@PEG}]$. Compared to other prevalent Mn_3O_4 -based NPs reported to date, $^{89}\text{Zr}[\text{Mn}_3\text{O}_4\text{@PEG}]$ NPs make full use of the high sensitivity of PET and soft-tissue contrast of MRI. The utilization of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4\text{@PEG}]$ for *in vivo* dual-modality PET/MR imaging and lymph node mapping provide successful examples for future clinical applications.

Acknowledgments

This work was supported, in part, by the University of Wisconsin-Madison, the National Institutes of Health (NIBIB/NCI1R01CA169365, 1R01CA205101, 1R01EB021336, T32GM008505, T32CA009206, and P30CA014520), the American Cancer Society (125246-RSG-13-099-01-CCE), the National Natural Science Foundation of China under Grant Nos. 81227901, 81571725, 81530058, 81230033, 31371006, 61405149, 81660505 and 81627807, the Natural Science Basic Research Plan in Shaanxi Province of China under Grant No. 2017JM8057, and the Fundamental Research Funds for the Central Universities (JB171204).

REFERENCES

1. Su T, Wang YB, Han D, Wang J, Qi S, Gao L, Shao YH, Qiao HY, Chen JW, Liang SH, Nie YZ, Li JY, Cao F. Multimodality imaging of angiogenesis in a rabbit atherosclerotic model by GEBP11 peptide targeted nanoparticles Theranostics. 2017; 7:4791. [PubMed: 29187904]
2. Su T, Wang Y, Wang J, Han D, Ma S, Cao J, Li X, Zhang R, Qiao H, Liang J, Liu G, Yang B, Liang S, Nie Y, Wu K, Li J, Cao F. *In vivo* magnetic resonance and fluorescence dual-modality imaging of tumor angiogenesis in rats using GEBP11 peptide targeted magnetic nanoparticles J. Biomed. Nanotechnol. 2016; 12:1011. [PubMed: 27305822]
3. Zamboglou C, Drendel V, Jilg CA, Rischke HC, Beck TI, Schultze-Seemann W, Krauss T, Mix M, Schiller F, Wetterauer U, Werner M, Langer M, Bock M, Meyer PT, Grosu AL. Comparison of ^{68}Ga -HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology Theranostics. 2017; 7:228. [PubMed: 28042330]
4. Shen B, Behera D, James ML, Reyes ST, Andrews L, Cipriano PW, Klukinov M, Lutz AB, Mavlyutov T, Rosenberg J, Ruoho E, McCurdy CR, Gambhir SS, Yeomans DC, Biswal S, Chin FT. Visualizing nerve injury in a neuropathic pain model with ^{18}F FTC-146 PET/MRI Theranostics. 2017; 7:2794. [PubMed: 28824716]

5. Li X, Feng J, Zhang R, Wang J, Su T, Tian Z, Han D, Zhao C, Fan M, Li C, Liu B, Feng X, Nie Y, Wu K, Chen Y, Deng H, Cao F. Quaternized chitosan/alginate-Fe₃O₄ magnetic nanoparticles enhance the chemosensitization of multidrug-resistant gastric carcinoma by regulating cell autophagy activity in mice *J. Biomed. Nanotechnol.* 2016; 12:948. [PubMed: 27305817]
6. Glaus C, Rossin R, Welch MJ, Bao G. *In vivo* evaluation of Cu-64-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent *Bioconjugate Chem.* 2010; 21:715.
7. Pichler BJ, Kolb A, Nagele T, Schlemmer HP. PET/MRI: Paving the way for the next generation of clinical multimodality imaging applications *J. Nucl. Med.* 2010; 51:333. [PubMed: 20150252]
8. Wang J, Tao W, Chen X, Farokhzad OC, Liu G. Emerging advances in nanotheranostics with intelligent bioresponsive systems *Theranostics.* 2017; 7:3915. [PubMed: 29109787]
9. Lee H, Lee E, Kim DK, Jang NK, Jeong YY, Jon S. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for *in vivo* cancer imaging *J. Am. Chem. Soc.* 2006; 128:7383. [PubMed: 16734494]
10. Ma LL, Feldman MD, Tam JM, Paranjape AS, Cheruku KK, Larson TA, Tam JO, Ingram DR, Paramita V, Villard JW, Jenkins JT, Wang T, Clarke GD, Asmis R, Sokolov K, Chandrasekar B, Milner TE, Johnston KP. Small multifunctional nanoclusters (nanoroses) for targeted cellular imaging and therapy *ACS Nano.* 2009; 3:2686. [PubMed: 19711944]
11. Wong RM, Gilbert DA, Liu K, Louie AY. Rapid size-controlled synthesis of dextran-coated, Cu-64-doped iron oxide nanoparticles *ACS Nano.* 2012; 6:3461. [PubMed: 22417124]
12. Yang XQ, Hong H, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, Xiao YL, Yang YA, Zhang Y, Nickles R, Cai WB, Steeber DA, Gong SQ. cRGD-functionalized, DOX-conjugated, and Cu-64-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging *Biomaterials.* 2011; 32:4151. [PubMed: 21367450]
13. Shapiro EM, Koretsky AP. *Magnetic Resonance in Medicine.* 2008; 60:265. [PubMed: 18666118]
14. Na HB, Lee JH, An KJ, Park YI, Park M, Lee IS, Nam DH, Kim ST, Kim SH, Kim SW, Lim KH, Kim KS, Kim SO, Hyeon T. Development of a T-1 contrast agent for magnetic resonance imaging using MnO nanoparticles *Angew. Chem. Int. Edit.* 2007; 46:5397.
15. Yu T, Moon J, Park J, Park YI, Na HB, Kim BH, Song IC, Moon WK, Hyeon T. Various-shaped uniform Mn₃O₄ nanocrystals synthesized at low temperature in air atmosphere *Chem. Mater.* 2009; 21:2272.
16. Jun YW, Lee JH, Cheon J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging *Angew. Chem. Int. Edit.* 2008; 47:5122.
17. Bennewitz MF, Lobo TL, Nkansah MK, Ulas G, Brudvig GW, Shapiro EM. Biocompatible and pH-sensitive PLGA encapsulated MnO nanocrystals for molecular and cellular MRI *ACS Nano.* 2011; 5:3438. [PubMed: 21495676]
18. Ha TL, Kim HJ, Shin J, Im GH, Lee JW, Heo H, Yang J, Kang AM, Choe YS, Lee JH, Lee IS. Development of target-specific multimodality imaging agent by using hollow manganese oxide nanoparticles as a platform *Chem. Commun.* 2011; 47:9176.
19. Hao R, Yu J, Hou YL, Sun SH. One-pot synthesis of hollow/porous Mn-based nanoparticles via a controlled ion transfer process *Chem. Commun.* 2011; 47:9095.
20. Shin JM, Anisur RM, Ko MK, Im GH, Lee JH, Lee S. Hollow manganese oxide nanoparticles as multifunctional agents for magnetic resonance imaging and drug delivery *Angew. Chem. Int. Edit.* 2009; 48:321.
21. Huang CC, Khu NH, Yeh CS. The characteristics of sub 10 nm manganese oxide T-1 contrast agents of different nanostructured morphologies *Biomaterials.* 2010; 31:4073. [PubMed: 20149451]
22. Huang J, Xie J, Chen K, Bu LH, Lee S, Cheng Z, Li XG, Chen XY. HSA coated MnO nanoparticles with prominent MRI contrast for tumor imaging *Chem. Commun.* 2010; 46:6684.
23. Yang XY, Zhou ZG, Wang L, Tang CZ, Yang H, Yang SP. Folate conjugated Mn₃O₄@SiO₂ nanoparticles for targeted magnetic resonance imaging *in vivo Mater. Res. Bull.* 2014; 57:97.
24. Hu H, Dai AT, Sun J, Li XY, Gao FH, Wu LZ, Fang Y, Yang H, An L, Wu HX, Yang SP. Aptamer-conjugated Mn₃O₄@SiO₂ core-shell nanoprobe for targeted magnetic resonance imaging *Nanoscale.* 2013; 5:10447. [PubMed: 24057072]

25. Yang H, Zhuang YM, Hu H, Du XX, Zhang CX, Shi XY, Wu HX, Yang SP. Silica-coated manganese oxide nanoparticles as a platform for targeted magnetic resonance and fluorescence imaging of cancer cells *Adv. Funct. Mater.* 2010; 20:1733.
26. Ranganathan A, Campo J, Myerson J, Shuvaev V, Zern B, Muzykantov V, Eckmann DM. Fluorescence microscopy imaging calibration for quantifying nanocarrier binding to cells during shear flow exposure *J. Biomed. Nanotechnol.* 2017; 13:737. [PubMed: 29104516]
27. Li N, Li T, Liu C, Ye S, Liang J, Han H. Folic acid-targeted and cell penetrating peptide-mediated theranostic nanoplatform for high-efficiency tri-modal imaging-guided synergistic anticancer phototherapy *J. Biomed. Nanotechnol.* 2016; 12:878. [PubMed: 27305812]
28. Cheng L, Shen S, Jiang D, Jin Q, Ellison PA, Ehlerding EB, Goel S, Song G, Huang P, Barnhart TE, Liu Z, Cai W. Chelator-free labeling of metal oxide nanostructures with zirconium-89 for positron emission tomography imaging *ACS Nano.* 2017; 11:12193. [PubMed: 29178789]
29. Wang Y, Liu Y, Luehmann H, Xia X, Brown P, Jarreau C, Welch M, Xia Y. Evaluating the pharmacokinetics and *in vivo* cancer targeting capability of Au nanocages by positron emission tomography imaging *ACS Nano.* 2012; 6:5880. [PubMed: 22690722]
30. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters G, Lambin P. Disparity between *in vivo* EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET *J. Nucl. Med.* 2009; 50:123. [PubMed: 19091906]
31. Tinianow JN, Gill HS, Ogasawara A, Flores JE, Vanderbilt AN, Luis E, Vandlen R, Darwish M, Junutula JR, Williams S-P. Site-specifically 89 Zr-labeled monoclonal antibodies for ImmunoPET *Nucl. Med. Biol.* 2010; 37:289. [PubMed: 20346868]
32. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression *in vivo* *J. Nucl. Med.* 2010; 51:1293. [PubMed: 20660376]
33. Cheng L, Yang K, Chen Q, Liu Z. Organic stealth nanoparticles for highly effective *in vivo* near-infrared photothermal therapy of cancer *ACS Nano.* 2012; 6:5605. [PubMed: 22616847]
34. Zhou M, Zhang R, Huang M, Lu W, Song S, Melancon MP, Tian M, Liang D, Li C. A chelator-free multifunctional [64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy *J. Am. Chem. Soc.* 2010; 132:15351. [PubMed: 20942456]
35. Chen F, Ellison PA, Lewis CM, Hong H, Zhang Y, Shi S, Hernandez R, Meyerand ME, Barnhart TE, Cai W. Chelator-free synthesis of a dual-modality PET/MRI agent *Angew. Chem. Int. Edit.* 2013; 52:13319.
36. Chakravarty R, Valdovinos HF, Chen F, Lewis CM, Ellison PA, Luo H, Meyerand ME, Nickles RJ, Cai W. Intrinsically germanium-69-labeled iron oxide nanoparticles: Synthesis and *in-vivo* dual-modality PET/MR imaging *Adv. Mater.* 2014:5119. [PubMed: 24944166]
37. Chen F, Goel S, Valdovinos HF, Luo H, Hernandez R, Barnhart TE, Cai W. *In vivo* integrity and biological fate of chelator-free zirconium-89-labeled mesoporous silica nanoparticles *ACS Nano.* 2015; 9:7950. [PubMed: 26213260]
38. Zhan Y, Ai F, Chen F, Valdovinos HF, Orbay H, Sun H, Liang J, Barnhart TE, Tian J, Cai W. Intrinsically zirconium-89 labeled Gd₂O₂S: Eu nanoprobes for *in vivo* positron emission tomography and gamma-ray-induced radioluminescence imaging *Small.* 2016; 12:2872. [PubMed: 27106630]
39. Ai F, Goel S, Zhan Y, Valdovinos HF, Chen F, Barnhart TE, Cai W. Intrinsically 89Zr-labeled Gd₂O₂S: Eu nanophosphors with high *in vivo* stability for dual-modality imaging *Am. J. Transl. Res.* 2016; 8:5591. [PubMed: 28078029]
40. Cheng L, Kamkaew A, Shen S, Valdovinos HF, Sun H, Hernandez R, Goel S, Liu T, Thompson CR, Barnhart TE. Facile preparation of multifunctional WS₂/WO_x nanodots for chelator-free 89Zr-labeling and *in vivo* PET imaging *Small.* 2016:5750. [PubMed: 27593416]
41. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, Bawendi MG, Frangioni JV. Renalclearance of quantum dots *Nat. Biotechnol.* 2007; 25:1165. [PubMed: 17891134]




Figure 1.

Characterization of Mn₃O₄@PEG NPs. (a) TEM images of Mn₃O₄; (b) TEM images of Mn₃O₄@PEG; (c) X-ray diffraction pattern of Mn₃O₄ NPs; (d) The FT-IR spectrum of DSPE-PEG-NH₂ (red line), Mn₃O₄ (blue line) and Mn₃O₄@PEG (black line).





Figure 2. The relaxation properties of $\text{Mn}_3\text{O}_4@PEG$ NPs. (a) T_1 -weighted MR imaging of $\text{Mn}_3\text{O}_4@PEG$ NPs; (b) T_1 relaxivity plot of aqueous suspensions of $\text{Mn}_3\text{O}_4@PEG$ NPs on a 7 T MRI system.

**Figure 3.**

Radiolabeling yield of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ NPs. (a) Time-dependent ^{89}Zr labeling yields of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ with varied temperature; (b) Autoradiography of TLC plates of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ (top) and free ^{89}Zr (bottom); (c) ^{89}Zr labeling yields of $^{89}\text{Zr}[\text{Mn}_3\text{O}_4@\text{PEG}]$ with varied concentrations.




Figure 4. Viability of human embryonic kidney 293 cells (HEK-293) and human gastric cells (SGC-7901) incubated with $Mn_3O_4@PEG$ NPs at different particle concentrations for 24 and 48 h. Black and blue bars indicate incubation with NPs, while red and green are controls.




Figure 5.

In vivo PET/MR imaging of $[^{89}\text{Zr}]\text{Mn}_3\text{O}_4@\text{PEG}$ NPs. (a) Serial *in vivo* PET imaging of $[^{89}\text{Zr}]\text{Mn}_3\text{O}_4@\text{PEG}$ in BALB/c mice at different post-injection time points; (b) Serial *in vivo* MR imaging of $\text{Mn}_3\text{O}_4@\text{PEG}$ in BALB/c mice at different postinjection time points ($n = 3$ per group).




Figure 6.

In vivo PET/MR imaging of lymph nodes with ^{89}Zr Mn_3O_4 @PEG NPs. (a) *In vivo* PET imaging acquired after subcutaneous injection of ^{89}Zr Mn_3O_4 @PEG NPs into the left footpad of the mouse ($n = 3$). Lymph nodes are indicated by arrows. (b) Quantification of the ^{89}Zr Mn_3O_4 @PEG NPs uptake by the lymph node, paw, heart, liver, kidney, blood, lung, muscle and spleen ($n = 3$). (c) *In vivo* MR imaging of the lymph nodes before and after injection of Mn_3O_4 @PEG NPs into the left footpad of the mouse ($n = 3$). Lymph nodes are indicated by circles.




Figure 7. *In vivo* biocompatibility studies of $\text{Mn}_3\text{O}_4@\text{PEG}$ in healthy mice. H&E staining of major organs from mice after injecting of $\text{Mn}_3\text{O}_4@\text{PEG}$ NPs (dose: 20 mg/kg) at 14 d post-injection. Healthy mice treated with PBS were used as the control ($n = 3$).





Figure 8.

Serum biochemistry of liver and kidney function markers. Healthy BALB/c mice were intravenously injected with $\text{Mn}_3\text{O}_4@\text{PEG}$ (dose: 20 mg kg^{-1}), and sacrificed on day 7 and day 14 post-injection ($n = 3$), the difference between AST in control and the treatment group on 14 days were statistically significant ($p < 0.05$).



Scheme 1.
The synthetic process of [^{89}Zr]Mn₃O₄@PEG NPs.